Unlocking Q1 Potential of MetLife (MET): Exploring Wall Street Estimates for Key Metrics

25.04.25 15:15 Uhr

Werte in diesem Artikel
Aktien

65,80 EUR -0,92 EUR -1,38%

Indizes

PKT PKT

16.240,1 PKT 197,2 PKT 1,23%

2.679,8 PKT 29,0 PKT 1,10%

5.525,2 PKT 40,4 PKT 0,74%

The upcoming report from MetLife (MET) is expected to reveal quarterly earnings of $1.99 per share, indicating an increase of 8.7% compared to the year-ago period. Analysts forecast revenues of $18.21 billion, representing an increase of 7% year over year.The consensus EPS estimate for the quarter has undergone a downward revision of 2.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.In light of this perspective, let's dive into the average estimates of certain MetLife metrics that are commonly tracked and forecasted by Wall Street analysts.It is projected by analysts that the 'Revenue- Premiums' will reach $10.97 billion. The estimate indicates a year-over-year change of +9.1%.Analysts expect 'Revenue- Other Revenues' to come in at $631.98 million. The estimate indicates a year-over-year change of -6.2%.The consensus among analysts is that 'Revenue- Universal life and investment-type product policy fees' will reach $1.27 billion. The estimate points to a change of +1.7% from the year-ago quarter.The combined assessment of analysts suggests that 'Revenue- Net investment income' will likely reach $5.27 billion. The estimate suggests a change of -3.1% year over year.The average prediction of analysts places 'Total Adjusted Revenue- Latin America' at $1.95 billion. The estimate suggests a change of +3.4% year over year.According to the collective judgment of analysts, 'Adjusted Revenue- Corporate & other- Net investment income' should come in at $107.65 million. The estimate suggests a change of +1.6% year over year.Based on the collective assessment of analysts, 'Total Adjusted Revenue- U.S. Business' should arrive at $10.64 billion. The estimate suggests a change of +11.5% year over year.The consensus estimate for 'Total Adjusted Revenue- EMEA' stands at $703.80 million. The estimate suggests a change of +4.4% year over year.Analysts predict that the 'Total Adjusted Revenue- Asia' will reach $2.99 billion. The estimate indicates a year-over-year change of +4.8%.The collective assessment of analysts points to an estimated 'Total Adjusted Revenue- Corporate & other' of $205.17 million. The estimate suggests a change of -2.3% year over year.Analysts forecast 'Adjusted Revenue- Asia- Net investment income' to reach $1.25 billion. The estimate indicates a change of +13% from the prior-year quarter.Analysts' assessment points toward 'Adjusted Revenue- EMEA- Net investment income' reaching $57.47 million. The estimate points to a change of +6.4% from the year-ago quarter.View all Key Company Metrics for MetLife here>>>Shares of MetLife have experienced a change of -8.7% in the past month compared to the -4.8% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), MET is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MetLife, Inc. (MET): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: MetLife und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf MetLife

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf MetLife

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu MetLife Inc.

Wer­bung

Analysen zu MetLife Inc.

DatumRatingAnalyst
02.01.2018MetLife HoldDeutsche Bank AG
03.11.2017MetLife OutperformRBC Capital Markets
25.05.2017MetLife OutperformFBR & Co.
09.12.2016MetLife HoldStandpoint Research
28.11.2016MetLife Mkt PerformFBR & Co.
DatumRatingAnalyst
03.11.2017MetLife OutperformRBC Capital Markets
25.05.2017MetLife OutperformFBR & Co.
05.05.2016MetLife OutperformRBC Capital Markets
31.07.2015MetLife BuyDeutsche Bank AG
22.06.2015MetLife OutperformRBC Capital Markets
DatumRatingAnalyst
02.01.2018MetLife HoldDeutsche Bank AG
09.12.2016MetLife HoldStandpoint Research
28.11.2016MetLife Mkt PerformFBR & Co.
13.07.2016MetLife HoldDeutsche Bank AG
15.03.2016MetLife NeutralUBS AG
DatumRatingAnalyst
04.12.2006Update MetLife Inc.: UnderperformFriedman, Billings Ramsey & Co
14.09.2005MetLife DowngradeDeutsche Securities
14.09.2005Update MetLife Inc.: SellDeutsche Securities

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für MetLife Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen